intuzumab + pyrrolidone + nab-paclitaxel

This is a combination drug consisting of three components: - **Intuzumab** (likely a misspelling or confusion with inotuzumab, which is a CD22-directed monoclonal antibody-drug conjugate used primarily for hematologic malignancies such as acute lymphoblastic leukemia)[2][3]. - **Pyrrolidone**, which refers to a chemical moiety and not an approved pharmaceutical agent on its own. Pyrrolidones are often used as excipients or solvents in drug formulations. - **Nab-paclitaxel** (nanoparticle albumin-bound paclitaxel), an albumin-bound formulation of the chemotherapy agent paclitaxel, designed to improve delivery and reduce toxicity compared to conventional paclitaxel. Nab-paclitaxel binds to the gp60 receptor on endothelial cells, facilitating transcytosis into tumor tissue and subsequent release of paclitaxel near tumor cells[1]. There is no evidence that this exact combination—intuzumab (or inotuzumab) plus pyrrolidone plus nab-paclitaxel—is an established or clinically recognized therapy. Nab-paclitaxel is approved for several solid tumors; inotuzumab ozogamicin targets hematologic cancers[1][2][3]. Pyrrolidone does not have direct antineoplastic activity.

Other names

intuzumab + pyrrolidone + nab-paclitaxel